Join the 'Leukine' group to help and get support from people like you.
Posted 4 Nov 2014 by Drugs.com
TUESDAY, Nov. 4, 2014 – Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds. Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the combination therapy, versus 53 percent for those on Yervoy alone, the researchers said. "Patients did live longer, as well as having less serious side effects, when given the combination," said lead researcher Dr. F. Stephen Hodi, an assistant professor of medicine at the Dana-Farber Cancer Institute in Boston. Melanoma is the most serious form of skin cancer. In the United States, more than 12,000 people die from advanced melanoma each year, the U.S. Centers for Disease Control and Prevention ... Read more
FDA Medwatch Alert: Leukine (sargramostim)
Posted 24 Jan 2008 by Drugs.com
[Posted 01/24/2008] Bayer and FDA informed healthcare professionals of the market withdrawal of the current liquid formulation of Leukine, a growth factor that helps fight infection and disease in appropriate patients by enhancing immune cell function. The product was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change in the formulation of liquid Leukine to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates has not been observed with the use of lyophilized Leukine. Healthcare professionals should immediately stop using liquid Leukine and return unused vials to the manufacturer.[January 23, 2008 - Dear Healthcare Professional Letter - Bayer Healthcare] Read more
Related support groups: Leukine